Radiation therapy before stem cell transplant for high-risk blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome with certain high-risk features (like not responding to treatment or having specific genetic changes).
- You need a donor whose tissue type is either fully matched or partly mismatched.
- Your heart, lungs, kidneys, and liver must be working well enough for this intense treatment.
- You cannot have received radiation to more than 20% of your bone marrow in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.